XNCR News and Press, Xencor Inc. From 02/24/20

Xencor (NASDAQ: XNCR ): Q4 GAAP EPS of -$0.47 misses by $0.04 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2019 financial results after the market closes on Monday, ...

Aimmune Therapeutics (NASDAQ: AIMT ) perks up  10%  premarket on average volume in reaction to its announcement that Nestlé Health Science will invest an additional $200M in the company, raising its stake to $473M (25.6% stake). More news on: Aimmune Therapeutics, Inc., Xe...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal...

Galmed Pharmaceuticals (NASDAQ: GLMD ) resumed with Overweight rating and $14 (142% upside) price target at Cantor Fitzgerald. More news on: Madrigal Pharmaceuticals, Inc., Xencor, Inc., Spring Bank Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology license agreement in which Gilead Sciences, Inc., ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its board of directors. Ms. Rosa-Bjork...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Allen Yang, M.D., Ph.D., as senior vice president and chief me...

Shares of Stemline Therapeutics ( STML ) have lost a third of their value since my August article recommended buying shares given the fact that the Q2 report showed progress on multiple fronts. Recently, at the ASH (American Society of Hematology) annual meeting, the company unveiled prom...